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Summary
Objective. Osteoclast activation at the cartilage pannus junction
is an essential step in the destruction of bone matrix in patients
affected by rheumatoid arthritis (RA). Receptor activator of
NFkappaB ligand (RANK-L) is responsible for osteoclast differ-
entiation and activation. Osteoprotegerin (OPG) is an alterna-
tive, high-affinity soluble receptor for RANK-L which signifi-
cantly inhibits osteoclastogenesis. Estrogens and the specific
receptors α and β (ER-α and ER-α) are known to play an impor-
tant role in the pathophysiology of osteoarthritis (OA). Scope of
the present study is to investigate the role of ER-α and OPG
gene polymorphisms in a group of women affected by RA.
Materials and Methods. 139 consecutive RA patients (115 fe-
males and 34 males; median age 65.8 years) were selected.
Bone mineral density (BMD) was measured by dual energy x-
ray absorptinometry at the lumbar spine (LS-BMD) and
femoral neck (FN-BMD) and the presence of bone erosions
was evaluated by conventional X-ray. ER-α gene polymor-
phisms were determined by PvuII and XbaI restriction endonu-
clease digestion of polymerase chain reaction (PCR) prod-
ucts. By convention, the presence of the endonuclease re-
striction site was indicated with lowercase (p and x) letters
while the absence of the restriction site was indicated with up-
percase letters (P and X). OPG gene polymorphism was deter-
mined by RsaI restriction endonuclease digestion of PCR
products and the presence and absence of restriction frag-
ment was identified as TT and CC respectively.
Results. Pearson’s χ2 analysis for the ER-α gene polymor-
phism showed a prevalence of Pp genotype (58%) (p=0.04)
and Xx (54%) (p=0.04) in the total population, without differ-
ences between males and females. We did not observed any
significant differences between ER-α genotypes and LS-BMD.
However subjects with xx or pp genotype had a lower LS-BMD
in comparison with the opposite genotype.
For OPG gene polymorphism, non significant differences in
the distribution of the genotypes were observed between
males and females. In addition, we did not observed signifi-
cant differences on LS-BMD between the genotypes.
Finally, we observed that patients with ER-α pp genotype was
significant more represented in patients with hand erosions (p
= 0.05). No significant correlation was observed for ER-α XbaI
genotype, however a trend characterized by a correlation be-
tween xx and hand erosions was observed (p = 0.13). For OPG
gene polymorphism, we found a statistical correlation be-
tween C allele of OPG and hands bone erosions (p = 0.02). 
Conclusion. We found a significant association between ER-α
and OPG gene polymorphisms and the presence of bone ero-
sions in RA patients. These preliminary data suggest a role of
ER-α and OPG gene polymorphisms in bone turnover and dis-
ease progression. 
KEY WORDS: estrogen receptor-alpha gene, osteoprotegerin gene, genet-
ics, rheumatoid arthritis.
Introduction
RA is characterized by inflammation of the synovial membrane,
leading to invasion of synovial tissue into the adjacent cartilage
matrix with degradation of cartilage and bone as a conse-
quence. This, results in erosion of bone, which is often radi-
ographically observed as marginal joint erosions and is predic-
tive of a poorer prognosis (1). The pathophysiological mecha-
nisms of cartilage and bone destruction in RA are yet to be
completely understood, however it is known that matrix metal-
loproteinases, cathepsins and mast cell proteinases can con-
tribute to cartilage and bone destruction (2-4). It is now clear
that osteoclast formation and activation at the cartilage–pannus
junction is an essential step in the destruction of bone matrix
patients with RA (5-8). A number of inflammatory cytokines
found in the RA synovial tissue (IL-1α, IL-1β, tumour necrosis
factor α (TNF-α) and macrophage colony-stimulating factor)
have the potential to promote osteoclast formation and bone
resorption (9-11). Recent evidences indicate that the interac-
tion between RANK-L and OPG has an essential role in osteo-
clastogenesis (5, 6, 12, 13). 
OPG is an alternative, high-affinity soluble decoy receptor for
RANK-L which blocks the interaction between RANK-L and
RANK and significantly inhibits osteoclastogenesis (14-15).
Similar to RANK and RANK-L, OPG production is stimulated by
proinflammatory cytokines, such as IL-1β and TNF-α (16).
RANK, RANK-L, and OPG are expressed in tissue of the RA
joint (5, 6, 8). 
Haynes et al. found that RANK-L is an essential factor for os-
teoclast formation by cells in the rheumatic joints and that OPG
may prevent the bone erosion seen in RA joints (8).
In view of its ability to block RANK-L-RANK interaction and in-
hibit osteoclast formation, OPG may have a role in normal
homeostasis within the joint and may be a potential therapeutic
factor alone or in combination with anti-inflammatory therapies
in RA. An important role in the regulation of bone mass, bone
turnover and immune response is also play by sex hormones.
The role of osteoprotegerin (OPG) and estrogen receptor
(ER-α) gene polymorphisms in rheumatoid arthritis
Article
It is well documented that androgens and estrogens modulate
susceptibility and progression to autoimmune rheumatic dis-
eases. At any concentration, androgens seem to be primarily
suppressive on cellular and humoral immunity, whereas at
physiologic concentrations estrogens seem to enhance hu-
moral immunity (17-19). In particular, low gonadal and adrenal
androgens [testosterone (T)/dihydrotestosterone (DHT), dehy-
droepiandrosterone (DHEA) and its sulfate (DHEAS)] levels, as
well as reduced androgens/estrogens ratio, have been detect-
ed in body fluids (i.e. blood, synovial fluid, smears, salivary) of
males and females with RA, supporting the possible pathogen-
ic role for the decreased levels of the immuno-suppressive an-
drogens (20). In addition, Jochems et al. observed that loss of
endogenous estrogens and the inflammation contribute equally
to bone loss in an animal model and, markers of bone and car-
tilage turnover, as well as bone marrow lymphocyte pheno-
types, indicate different mechanisms for bone loss induced by
estrogen deficiency and inflammation, respectively (21). In ad-
dition, genetic factors might further interfere with the roles of
androgens and estrogens in selected individuals (18). 
It has been reported that 15.4% of the monozygotic twins were
disease concordant for RA (22). Recently, the existence of an
ER gene polymorphism has been made clear, and its associa-
tion to some variant ER genotypes with breast cancer (23, 24),
hypertension (25), generalised osteoarthritis (26) and osteo-
porosis (27), has been reported.
Genetic factors play an important role in the determination of
bone mass and osteoporosis. A number of candidate genes
have been implicated in osteoporosis, including genes encod-
ing type 1 collagen, vitamin D receptor, ER-α, and others (28).
A number of association studies have been performed with sin-
gle nucleotide polymorphisms in the ER-α gene to assess their
relation with bone mineral density in pre- and postmenopausal
women, as well as the rate of bone loss after menopause and
skeletal response to estrogen administration (29).
Assessing genetic factors may be helpful in targeting preventive
measures to individuals with higher risk of developing osteoporo-
sis and provide the preventive effort more cost-effective. 
The aim of our study is to investigate the association between
ER-α and OPG genes polymorphisms in RA.
Materials and methods 
Patients
Our study population included 139 consecutive Italian patients
(115 females and 34 males; median age 65.8 years, range 24-
89 years, mean disease duration 8.5 ± 3.2 SD years) affected
by RA referred to the Section of Rheumatology of the Depart-
ment of Internal Medicine of the University of Florence, Italy.
They all fulfilled the American College of Rheumatology criteria
(30). Sixty seven had rheumatoid factor positive and seven two
had rheumatoid factor negative. As regard the therapy all pa-
tients with active disease (polyarthritis or extended oligoarthri-
tis) were receiving treatment with methotrexate or hydroxy-
chloroquine and low dose of steroid or non-steroidal anti-in-
flammatory drugs (NSAIDs); patients in remission were treated
with low dose of steroid or NSAID therapy.
ESR (erytrocite sedimentation rate), CRP (C-reactive protein),
disease duration and bone erosion were considered as disease
indexes. 
Bone erosions
Bone erosions were detected by conventional X-rays.
Bone mineral density
Bone status was evaluated at the time of the study using dual-
X ray absorptiometry (DXA) devices (Hologic QDR 1000/W,
Waltham, MA, USA) at the lumbar spine (L2-L4, posterior ante-
rior) and femoral neck.
We set a cut-off point for osteoporosis at a T score of less than
-2.5. 
Determination of genotype
After informed consent was obtained, blood samples were
drawn during routine follow-up hematological tests. Genomic
DNA was isolated from EDTA blood samples by a standard
phenol-chloroform extraction procedure.
For OPG polymorphism, genomic DNA was amplified by poly-
merase chain reaction (PCR) as indicated by Wuyts et al. (31).
PCR was carried out and products were digested by Pst I en-
zyme (New England, Biolabs, Beverly, MA, USA) under condi-
tions recommended by the manufacturer and electrophoresed
in 3% NuSive and 1% Agarose. Pst I restriction site was intro-
duced in the presence of T allele. The presence or absence of
the restriction site was indicated as TT and CC respectively.
The heterozygous were indicated as CT.
Genotyping for the ER-α gene polymorphisms was performed
using PCR-RFLP, single base extension sequencing, and 5’ nu-
clease Taqman assays for the XbaI and PvuII polymorphisms
(27). For XbaI and PvuII, X and P denote the absence of the re-
spective restriction sites (G-allele and C-allele, respectively).
Statistical analysis
Analysis of covariance (ANCOVA), followed by LSD protected
(least significant difference), was performed in order to evaluate
the correlation between OPG polymorphisms and LS-BMD val-
ues. Results were expressed as means ± SEM. The following
covariates were considered for the ANCOVA analysis: sex, age,
body mass index, and disease duration. For the assessment of
OPG and ER-α polymorphism distribution in the total population
the Pearson’s chi-square (χ2) analysis was applied (Odd ratios
with 95% confidence intervals). This test was also performed to
evaluate the frequency of bone erosions between ER-a and
OPG genotypes in the population. All tests were perfomed using
Statistica 5.1 program (Statsoft Inc., Tulsa, OK, USA).
Results
ER-α gene polymorphism
Pearson’s χ2 analysis showed a prevalence of Pp genotype
(58%) (p = 0.04) and Xx (54%) (p = 0.04) in the total popula-
tion, without differences between male and female. ANCOVA
analysis and LSD test did not shown any statistically significant
differences between the ER-α genotypes and LS-BMD. How-
ever, a trend characterized by a lower LS-BMD was observed
in subjects with xx or pp genotypes (Fig. 1).
In addition, we observed that patients with pp genotype was
significant more represented in patients with hand erosions (p
= 0.05) (Fig. 2). No significant correlation was observed for
XbaI polymorphism. However, a trend of correlation between
xx and hand erosions was observed (p = 0.13). Finally, no sta-
tistically significant association between the disease markers
and ER-α genotypes was observed (data not shown) but a
trend of correlation between pp genotype and the presence of
rheumatoid factor was found.
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OPG gene polymorphism
Pearson’s χ2 analysis showed a prevalence of CC (78%) in the
total population. No significant differences in the distribution of
the genotypes were observed between male and female. 
ANCOVA analysis and LSD test did not shown any statistically
significant differences between the OPG genotypes and 
LS-BMD (Fig. 3).
A statistically significant correlation between C allele of OPG
and hands bone erosions (p = 0.02) (Fig. 4) was observed. Fi-
nally, not significant association between the presence of
rheumatoid factor and OPG gene polymorphism was found. 
Discussion
Genetic factors play an important role in the regulation of BMD
and risk of osteoporotic fractures in both men and women (32-
34). 
In the present study, we evaluated the role of OPG and ER-α
gene polymorphisms in patients with RA. It is well known that
OPG knockout mice exhibit a decrease in total BMD and a high
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Figure 2 - Percent of bone erosions between PvuII genotypes. Bone
erosions were more frequent in patients with pp genotypes (Pearson’s
χ2 test: p = 0.05). The grey bar represent the percent of subjects with
bone erosion and white bar the percent of subjects without bone ero-
sions.
Figure 4 - Percent of bone erosions between OPG genotypes. Bone
erosions were more frequent in patients with CC genotype (Pearson’s
χ2 test: p = 0.02). The grey bar represent the percent of subjects with
bone erosion and white bar the percent of subjects without bone ero-
sions.
Figure 3 - Differences in the LS-BMD between the OPG gene polymor-
phism. No significant differences were observed between genotypes
(ANCOVA analysis).
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Figure 1 - Differences in the LS-BMD between the ER-α gene polymor-
phisms (XbaI and PvuII). A: no significant differences were observed
between XbaII genotypes; B: no significant differences were observed
between PvuII genotypes, however a trend characterized by a lower
LS-BMD was observed in patients with xx and pp genotypes (ANCOVA
analysis).
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incidence of fracture due to enhanced osteoclastogenesis (35)
suggesting that OPG gene would be a candidate gene for in-
vestigation into susceptibility to osteoporosis in humans. We
did not found a significant association between OPG geno-
types and LS-BMD in RA patients, however, a positive associa-
tion between OPG polymorphism and hands bone erosions
was observed. These data are in accord with the data pub-
lished by Langdahl et al. (36). The presence of C allele identi-
fied in intron 2 of the OPG gene exhibits a significant associa-
tion with bone erosions. 
Bone and articular cartilage destruction can be prevent by
OPG treatment in arthritic rats (37). The polymorphism of the
OPG gene could be important as a disease index. In particular
C allele could be associated with a imbalance between
OPG/RANK-RANK-L and could causes an insufficient produc-
tion of OPG. This OPG gene sequence variation is an intronic
polymorphism close to the splice junction of the exon 3 and
could in theory affect splicing efficiency. Several OPG gene
polymorphisms have been described in the literature (38). In
this study we evaluated the polymorphism localized in the in-
tron 2, described for the first time by Wuyts et al. (31). These
authors found a higher frequency of C allele in subject affected
by Paget’s disease. In addition, we previously observed a sig-
nificant association between this polymorphism and LS-BMD in
children affected by Juvenile Idiopathic Arthritis (39). The dis-
crepancy with the present results could be due to differences
between adult and pediatric population where several environ-
mental factors could modify the results. However, this data is in
accord with a recent study which found a negative correlation
between OPG polymorphism and BMD at the lumbar spine but
not at the femoral neck site in postmenopausal women (38). 
Bone loss is a major unsolved problem in RA, a disease char-
acterized by chronic synovial inflammation and hyperplasia
culminating in joint destruction (40, 41). Until recently, the
processes underlying these types of bone loss were thought to
be separate. Thus, focal bone erosions in RA were considered
to be due to direct invasion by the inflamed synovial mem-
brane (SM, also referred to as “pannus”). The juxtaarticular
osteoporosis was considered to be secondary to increased lo-
cal production of osteoclast-activating cytokines, whereas
generalized osteoporosis was regarded as multifactorial, es-
pecially as a consequence of loss of mobility or long-term use
of corticosteroids. Now, the recognition of osteoclasts as one
of the pivotal effectors cells in the pathogenesis of bone and
joint damage in RA, together with elucidation of receptor acti-
vator of RANK-L, OPG, and RANK as central regulators of os-
teoclast recruitment and activation, point to a unifying para-
digm for the entire spectrum of skeletal pathology in RA and
provide a chance for powerful new therapeutic interventions. 
In addition, it has been shown that estrogens loss up-regulates
osteoclastogenesis through an increase in the production of in-
terleukin 6 (IL-6) in the microenvironment of the bone tissue,
resulting in osteoporosis (42). On the other hand, the concen-
tration of IL-6 is increased in the synovial fluids of RA patients,
and IL-6 is believed to play important part in immune response
and activation of inflammation at articular joints (43). It is al-
ready known that articular chondrocytes and synovial cells ex-
press ER (44) and that estrogens induces the up-regulation of
IL-6 production by chondrocytes, showing a conspicuous differ-
ence from bone tissue (45). It is therefore probable that women
who show a specific reaction to the hormonal stimuli may tend
to develop either osteoporosis in bone tissue at the post-
menopausal period or rheumatoid inflammation in joint tissues
at the premenopausal period through different effects of estro-
gens toward IL-6 production. 
Because estrogens have important effects on bone mass and
bone remodelling (4, 5), many investigators have evaluated the
role of ER-α gene polymorphisms in the genetic regulation of
BMD. In the present study we found that subjects with xx or pp
genotype for the ER-α gene polymorphisms had a lower LS-
BMD in comparison with the opposite genotype. We have not
found any association between ER-α gene polymorphisms and
FN-BMD. These data are in accord with the meta-analysis re-
ported for PvuII, XbaI, and promoter TA repeats with BMD and
fractures in 18,917 individuals from eight European research
centers (46). None of the three polymorphisms or haplotypes
had statistically significant association with BMD. However,
there was a highly significant protection conferred by the XbaI
XX genotype against fracture risk. In women with the XX geno-
type, the OR was 0.81 (p = 0.002) for any fractures and 0.65 (p
= 0.003) for vertebral fractures. The observed effects on frac-
tures were independent of BMD (46). In the present study, no
data on fractures were available. However, the association be-
tween xx genotype and hand bone erosion make possible to
speculate that ER-α gene polymorphism could play a role in
the control of cartilage and bone quality influencing some para-
meters which are not involved in the regulation of bone mass. 
The molecular mechanism by which PvuII and XbaI polymor-
phisms influence bone mass and osteoporotic risk are still un-
clear, mainly because these polymorphism lie in an intronic
and apparently nonfunctional area of the gene. A possible ex-
planation is that the two polymorphisms in intron I should be in
linkage disequilibrium with causal polymorphism that lie else-
where in the ER-α gene, or in adjacent genes (47). In conclu-
sion, these preliminary data suggests a possible role of OPG
and ER-α gene polymorphisms in the regulation of bone miner-
al density, bone erosion and disease progression. Therefore,
further study and a larger number of populations are required
to elucidate a possible relationship between OPG and ER-α
gene polymorphisms.
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